Page last updated: 2024-11-02

pd 98059 and Tuberous Sclerosis

pd 98059 has been researched along with Tuberous Sclerosis in 1 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mi, R1
Ma, J1
Zhang, D1
Li, L1
Zhang, H1

Other Studies

1 other study available for pd 98059 and Tuberous Sclerosis

ArticleYear
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Journal of genetics and genomics = Yi chuan xue bao, 2009, Volume: 36, Issue:6

    Topics: Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; Extracellular

2009